FiercePharma5h
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
pharmaphorum1d
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
Belgian biopharma company UCB is bringing up the rear of the IL ... expiries for the Belgian drugmaker’s current top-selling product Cimzia (certolizumab pegol), due in Europe in 2021 and ...
Hosted on MSN11mon
Samsung Biologics inks US$352.7 mln deal with Belgium-based UCB
SEOUL, March 6 (Yonhap) -- Samsung Biologics Co. said Wednesday it has signed a US$352.7 million deal with Belgium-based biopharmaceutical firm UCB to manufacture the latter's products. The deal ...
Pharmaceutical Technology14d
Top 20 biopharma companies’ market caps rise 1.7% over 2024 amid policy
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various factors.
pharmaphorum3y
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis
UCB has been bringing up the rear in the IL-17 ... patent expiries for the Belgian drugmaker's current top-selling product Cimzia (certolizumab pegol), due in Europe this year and in the US ...
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...
PharmiWeb14d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...